Modeling long-term persistence after 8 years of hepatitis B booster vaccination in 5- to 15-year-old children
Open Access
- 4 May 2022
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2061247
Abstract
Vaccination remains the most effective and cost-saving measure to protect against hepatitis B, a global health problem. It is crucial to characterize the persistence of the immune response after booster vaccination. This study aimed to quantify the persistence through mathematical modeling. Booster vaccination against hepatitis B was conducted in children 5–15 years in 2009–10 in Zhejiang Province. There were four dosage formulations of hepatitis B vaccines [Shenzhenkangtai Biotechnology Co. Ltd. Dalianhanxin Biotechnology Co. Ltd. NCPC GeneTech Biotechnology Pharmaceutical Co. Ltd. Sinovac Biotech Co. LTD. China]: 5, 10, and 20 μg hepatitis B vaccines or 5 μg hepatitis A and B (HAB) combination vaccine with a 0-1-6-month schedule. These were randomly administered to children negative for all hepatitis B markers, named as the schedule 2 group. Anti-HBs positive subjects were given one dose of booster, named as the schedule 1 group. Anti-HBs antibody was measured 1, 7, 18, 66, and 102 months after the first booster dose. A linear mixed-effects model was proposed to predict long-term persistence. One hundred two months after the booster dose, the mean anti-HBs levels were 33.8 mIU/mL, with 73.7 mIU/mL for the schedule 1 group and 20.2 mIU/mL for the schedule 2 group. The model predicted that 99.5% of subjects would remain seropositive (≥10mIU/mL) at year 20 post booster vaccination, with 100.0% and 98.8% for the schedule 1 group and the schedule 2 group, respectively, whereas at year 30, the seropositivity rates would decrease to 76.8%, with 99.4% for the schedule 1 group and 62.5% for the schedule 2 group. The immunogenicity of the booster vaccination could persist for at least 8 years. Mathematical modeling may predict even longer, up to 30 years of protection.Keywords
Funding Information
- the National Scientific and Technological Major Project of China (No.2013ZX10004904)
This publication has 22 references indexed in Scilit:
- Immunity to hepatitis B persists in adolescents 15–16 years of age vaccinated in infancy with three doses of hepatitis B vaccineVaccine, 2016
- Healthy adult vaccination: An urgent need to prevent hepatitis B in ChinaHuman Vaccines & Immunotherapeutics, 2015
- Lasting immune memory against hepatitis B following challenge 10–11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11–12 months of ageVaccine, 2015
- The global burden of liver disease: The major impact of ChinaHepatology, 2014
- Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adultsVaccine, 2014
- Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicityVaccine, 2012
- [Application of exponent curve model to study the hepatitis B DNA recombinant yeast derived vaccine antibody levels].2004
- A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis BClinical and Experimental Immunology, 1999
- Scheduling of revaccination against hepatitis B virusThe Lancet, 1991
- Estimating the Dimension of a ModelThe Annals of Statistics, 1978